Eyenovia Inc (EYEN)
0.7713
-0.03
(-4.14%)
USD |
NASDAQ |
May 10, 16:00
0.75
-0.02
(-2.76%)
After-Hours: 07:29
Eyenovia Research and Development Expense (Quarterly): 4.065M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.065M |
| September 30, 2023 | 3.578M |
| June 30, 2023 | 2.811M |
| March 31, 2023 | 2.522M |
| December 31, 2022 | 2.202M |
| September 30, 2022 | 3.877M |
| June 30, 2022 | 3.587M |
| March 31, 2022 | 3.713M |
| December 31, 2021 | 3.292M |
| September 30, 2021 | 3.552M |
| June 30, 2021 | 3.685M |
| March 31, 2021 | 4.323M |
| December 31, 2020 | 3.45M |
| September 30, 2020 | 3.364M |
| June 30, 2020 | 2.915M |
| Date | Value |
|---|---|
| March 31, 2020 | 3.634M |
| December 31, 2019 | 3.324M |
| September 30, 2019 | 3.201M |
| June 30, 2019 | 3.568M |
| March 31, 2019 | 4.009M |
| December 31, 2018 | 4.125M |
| September 30, 2018 | 2.488M |
| June 30, 2018 | 2.412M |
| March 31, 2018 | 2.094M |
| December 31, 2017 | 1.584M |
| September 30, 2017 | 0.5704M |
| June 30, 2017 | 0.7519M |
| March 31, 2017 | 0.9108M |
| December 31, 2016 | 0.9806M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.202M
Minimum
Dec 2022
4.323M
Maximum
Mar 2021
3.403M
Average
3.552M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| NovaBay Pharmaceuticals Inc | 0.004M |
| Alpine Immune Sciences Inc | 22.93M |
| Lantern Pharma Inc | 3.573M |
| Oragenics Inc | 11.04M |
| MAIA Biotechnology Inc | 3.717M |